| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT00848016 | Recurrent Adrenocortical Carcinoma|Stage III Adrenocortical Carcinoma|Stage IV Adrenocortical Carcinoma | Drug: R-(-)-gossypol acetic acid | National Cancer Institute (NCI) | Phase 2 | 2009-02-01 | 2014-04-17 |
| NCT00544596 | Extensive Stage Small Cell Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific | Drug: R-(-)-gossypol acetic acid|Drug: cisplatin|Drug: etoposide | National Cancer Institute (NCI) | Phase 1 | 2007-09-01 | 2014-04-01 |
| NCT00540722 | Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor | Drug: R-(-)-gossypol acetic acid|Other: laboratory biomarker analysis | National Cancer Institute (NCI) | Phase 2 | 2008-01-01 | 2016-12-27 |
| NCT01977209 | Non-small Cell Lung Cancer | Drug: Gossypol|Drug: Placebo | Third Military Medical University | Phase 3 | 2013-09-01 | 2013-10-30 |
| NCT00773955 | Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer | Drug: R-(-)-gossypol acetic acid|Other: pharmacological study|Other: laboratory biomarker analysis | National Cancer Institute (NCI) | Phase 2 | 2008-11-01 | 2014-04-23 |
| NCT00934076 | Carcinoma, Non Small Cell Lung | Drug: Tarceva plus AT-101 | University of Alabama at Birmingham|Ascenta Therapeutics | Phase 1 | 2010-02-01 | 2015-05-06 |
| NCT00286780 | Chronic Lymphocytic Leukemia | Drug: AT-101 | Ascenta Therapeutics | Phase 2 | 2006-01-01 | 2010-08-12 |
| NCT00286793 | Prostate Cancer | Drug: AT-101 | Ascenta Therapeutics | Phase 1|Phase 2 | 2006-02-01 | 2011-06-27 |
| NCT00666666 | Adenocarcinoma of the Prostate|Stage IV Prostate Cancer | Drug: AT-101|Drug: Bicalutamide|Other: LHRH agent | National Cancer Institute (NCI) | Phase 2 | 2009-07-01 | 2014-12-17 |
| NCT00561197 | Locally Advanced Esophageal or GE Junction Cancer | Drug: AT-101 | Ascenta Therapeutics | Phase 1|Phase 2 | 2007-08-01 | 2013-01-03 |
| NCT01003769 | Recurrent Chronic Lymphocytic Leukemia | Drug: Lenalidomide|Drug: R-(-)-Gossypol Acetic Acid|Other: Laboratory Biomarker Analysis | Mayo Clinic|National Cancer Institute (NCI) | Phase 1|Phase 2 | 2013-09-01 | 2016-06-20 |
| NCT02697344 | Recurrent Plasma Cell Myeloma | Drug: Dexamethasone|Other: Laboratory Biomarker Analysis|Drug: Lenalidomide|Other: Pharmacological Study|Drug: R-(-)-Gossypol Acetic Acid | Mayo Clinic|National Cancer Institute (NCI) | Phase 1|Phase 2 | 2016-04-01 | 2016-10-20 |
| NCT00891072 | Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenstr枚m Macroglobulinemia | Drug: R-(-)-gossypol acetic acid|Drug: paclitaxel|Drug: carboplatin|Other: pharmacological study | National Cancer Institute (NCI) | Phase 1 | 2009-07-01 | 2013-01-09 |
| NCT00988169 | Lung Cancer | Drug: oral erlotinib and pulsed doses of oral AT-101 | Memorial Sloan Kettering Cancer Center|Ascenta Therapeutics | Phase 2 | 2009-09-01 | 2015-10-19 |
| NCT00544960 | Non-small Cell Lung Cancer | Drug: AT-101 and docetaxel|Drug: placebo and docetaxel | Ascenta Therapeutics | Phase 2 | 2007-09-01 | 2010-08-24 |
| NCT00571675 | Hormone Refractory Prostate Cancer | Drug: AT-101, prednisone and docetaxel|Drug: placebo, prednisone and docetaxel | Ascenta Therapeutics | Phase 2 | 2007-10-01 | 2010-11-08 |
| NCT00397293 | Small Cell Lung Cancer | Drug: AT-101|Drug: topotecan | Ascenta Therapeutics | Phase 1|Phase 2 | 2006-11-01 | 2010-08-20 |
| NCT00440388 | Follicular Lymphoma | Drug: AT-101|Drug: Rituximab | Ascenta Therapeutics | Phase 2 | 2006-10-01 | 2010-08-24 |
| NCT00275431 | Follicular Lymphoma|Diffuse Large Cell Lymphoma|Mantle Cell Lymphoma|Small Lymphocytic Lymphoma|Chronic Lymphocytic Leukemia | Drug: AT-101 | Ascenta Therapeutics | Phase 2 | 2005-11-01 | 2011-06-24 |
| NCT01285635 | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Drug: AT-101|Drug: Docetaxel | University of Michigan Cancer Center | Phase 2 | 2010-06-01 | 2016-03-03 |
